Oncotarget is described as a weekly peer-reviewed medical journal with open access to all readers. The journal covers scientific research on matters that concern oncology. Oncotarget was founded in 2010. It has grown to become an internationally read journal. Oncotarget tops the list of all journals that cover oncology in the world. The Impact Journals usually publish the Journal. It has many editors working on it. The editors-in-chief of Oncotarget include Andrei V. Gudkov and Mikhail Blagosklonny. These two also serve as scientists at the Roswell Park Cancer Institute. Oncotarget releases new issues and papers to its readers every week. The popularity for Oncotarget has been on the rise because of constructive, insightful, punctual, and multiple peer- reviews. Carlo M. Croce is a former editor-in-chief at the Cancer Research, and Andrew Schally is a winner of the Nobel Prize. They both serve as members of the Editorial Board at Oncotarget. Four Oncotarget members managed to win the Breakthrough Prize. It is the highest prize. These members include Alexander Varshavsky, Bert Vogelstein, Stephen Elledge, and Michael Hall. Oncotarget is the official sponsor of Gordon Research Conference. The editorial team at Oncotarget is outstanding. They have extensive knowledge in the field of oncology.
Oncotarget covers all cellular functions frequent in aging and cancer, molecules, pathways, lymphocytes, microbes, cancer cells, neurons, atherosclerosis, and neurodegeneration. Oncotarget has decided to venture into other fields beyond oncology due to its success in Oncology. These include Chromosome, Aging and Gerotarget, Microbiology and immunology, pathology, Pharmacology, Cell Biology, Endocrinology, Metabolism, and Neuroscience. The ultimate goal of Oncotarget is to ensure that there is rapid and extensive availing of scientific results. Follow Oncotarget on Twitter.
Oncotarget also seeks to make the impact of research maximum through insightful review and to ensure that there is rapid sharing of exceptional discoveries. Another mission of this peer-reviewed journal is to remove the border that has been in existence between specialties. Every paper or issue can be printed if a reader has a special demand. Oncotarget hopes to promote the application of clinical and basic science in the battle against the disease. Download output styles at Endnote.com
Mikhail Blagosklonny is an oncology professor for the Roswell Park Cancer on nature.com. He studied for his medical degree at the First Pavlov State Medical University of St. Peterburg. He also went on to teach at the New York Medical College.
His first major position was at the Ordway Research Institute as a senior scientist. He finally moved on to the Roswell Park Cancer Institute to study cancer and aging related diseases. Much of his work has been studying drugs in relation to theoretical life extension.
Mikhail is popularly known for his unusual theory of the role of TOR signaling in aging. He has suggested that the usage of Sirolimus(rapamycin) can be used to directly reduce the aging process. This drug is typically used during organ transplants and for experimental cancer treatments on tandfonline.com. There is still much debate around this theory to this day.
Mikhail Blagosklonny produces many publications in relation to hematology, clinical trials and oncology. A recent publication was about his research on how Dual MTORC1/C2 inhibitors can reduce cellular geroconversion. He also analyzed a rat study that proves that Sirolimus reduces benign prostate hyperplasia in rats.
Mikhail Blagosklonny had also made an interesting publication discussing the relationship between calorie restriction and longevity. He named this paper Koschei the immortal and anti-aging drugs. Koschei was an immortal person that was very popular in Norther European and Slavic folklore that ate very little and had a bony body. He also discusses the benefits of combing Sirolimus, metformin and other theoretical life extending drugs with calorie restriction.
He also oversaw the study of rats being fed a high fat diet and used rapamycin to prevent fat gain. The study showed that the rats eating a high fat diet gained a lot of weight at the low fat diet prevented any weight gain. Source: http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=3740